ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0928

Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model

Annemarie Kip1, Daphne Dorst2, Birgitte Walgreen2, Monique Helsen2, Eric meldrum1, Renato Chirivi1 and Marije Koenders2, 1Citryll BV, Oss, Netherlands, 2RadboudUMC, Nijmegen, Netherlands

Meeting: ACR Convergence 2025

Keywords: citrullination, Imaging, innate immunity, neutrophils, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Neutrophil Extracellular Traps (NETs) contribute to the pathophysiology of multiple immune-mediated inflammatory diseases including Rheumatoid Arthritis (RA), and may be promising therapeutic targets. The first-in-class therapeutic anti-citrullinated histone antibody CIT-013 binds citrullinated histones H2A and H4 in NETs and has demonstrated efficacy in models of NET-mediated inflammation by inhibiting de novo NET formation and by enhancing clearance of existing NETs by Fc receptor-mediated phagocytosis (Chirivi et al 2021; van der Linden et al 2024).In this study, we describe the use of a NET targeting antibody as an in vivo radiotracer to detect and visualize NETs in inflamed tissues.

Methods: Mice with collagen induced arthritic (CIA) mice with no, mild, moderate and established disease (n=10/group) were intravenously injected with indium-111 labeled mouse anti-citrullinated histone antibody (mACHA). Twenty-four hours after injection, whole body Single Photon Emission Computed Tomographic (SPECT) imaging was performed on selected animals. For all animals, tissue distribution of the radiotracer was quantified ex vivo by measuring gamma radiation.

Results: In CIA mice, indium-111 labeled mACHA distributes to inflamed joints and can be detected in animals with mild inflammation with increasing accumulation of the radiotracer in the fore and hind paws correlating with higher arthritis severity. Furthermore, the radiotracer enables a highly sensitive detection of inflammation in joints not apparently inflamed upon visual inspection, such as the knee.

Conclusion: mACHA can be used as a radiotracer to visualize NETs in sites of inflammation. This proof of principle imaging study enables a human whole body PET CT imaging clinical study in RA and hidradenitis suppurativa patients during 2025. This clinical study will lead to further insights in CIT-013’s distribution, target engagement and mechanism of action in patients with immune mediated inflammatory diseases.


Disclosures: A. Kip: Citryll BV, 3, 5, 11; D. Dorst: Citryll, 12, Contract research; B. Walgreen: None; M. Helsen: None; E. meldrum: Citryll BV, 3, 3, 5, 11, 11; R. Chirivi: Citryll BV, 3, 5, 8, 10, 11; M. Koenders: BIRR, 7, Contura, 7, Eli Lilly, 5, Genmab, 7, Lemba Therapeutics, 7.

To cite this abstract in AMA style:

Kip A, Dorst D, Walgreen B, Helsen M, meldrum E, Chirivi R, Koenders M. Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/radiolabelled-anti-citrullinated-histone-antibody-cit-013-as-a-tool-to-visualize-net-rich-inflamed-joints-in-a-collagen-induced-arthritic-mouse-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiolabelled-anti-citrullinated-histone-antibody-cit-013-as-a-tool-to-visualize-net-rich-inflamed-joints-in-a-collagen-induced-arthritic-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology